[{"data":1,"prerenderedAt":232},["ShallowReactive",2],{"$fcrh4gout7spl":3},{"schema":4,"slug":5,"series":6,"series_slug":7,"name":8,"year":9,"therapeutic_area":10,"generated_at":11,"counts":12,"top_targets":21,"top_modalities":58,"top_diseases":86,"top_companies":115,"key_results":146,"trends":219,"previous_editions":228,"comparison":206,"highlighted_classes":229},1,"endo-2026","ENDO","endo","ENDO (Endocrine Society Annual Meeting) 2026",2026,"Endocrinology & Metabolism","2026-11-05T22:19:09Z",{"abstracts":13,"drug_linked":14,"companies":15,"by_phase":16},2938,1558,157,{"Phase 1":17,"Phase 1\u002F2":4,"Phase 2":18,"Phase 4":19,"Phase 2\u002F3":4,"Phase 3":20},11,23,3,31,[22,26,29,33,37,40,44,48,51,54],{"name":23,"count":24,"share":25},"GR",132,8,{"name":27,"count":28,"share":25},"GLP1R",120,{"name":30,"count":31,"share":32},"THRB",102,7,{"name":34,"count":35,"share":36},"THR",100,6,{"name":38,"count":39,"share":36},"THRA",98,{"name":41,"count":42,"share":43},"INSR",75,5,{"name":45,"count":46,"share":47},"TPO",60,4,{"name":49,"count":50,"share":47},"GIPR",57,{"name":52,"count":53,"share":19},"AR",49,{"name":55,"count":56,"share":57},"FDPS",38,2,[59,63,67,71,74,77,80,83],{"name":60,"count":61,"share":62},"Small molecules",1040,67,{"name":64,"count":65,"share":66},"Peptides",277,18,{"name":68,"count":69,"share":70},"Non-antibody therapeutic proteins",190,12,{"name":72,"count":73,"share":17},"Monoclonal antibodies",169,{"name":75,"count":76,"share":57},"Radiopharmaceuticals",36,{"name":78,"count":79,"share":57},"Carbohydrate, lipid and polymer therapeutics",24,{"name":81,"count":82,"share":4},"Oligonucleotide and RNA therapeutics",17,{"name":84,"count":32,"share":85},"Blood, tissue and cell-derived products",0,[87,91,93,97,100,103,106,109,111,113],{"name":88,"count":89,"share":90},"type 2 diabetes mellitus (T2DM)",203,13,{"name":92,"count":73,"share":17},"obesity",{"name":94,"count":95,"share":96},"hypothyroidism",156,10,{"name":98,"count":99,"share":36},"hypertension (HTN)",88,{"name":101,"count":102,"share":36},"hypoadrenocorticism",86,{"name":104,"count":105,"share":43},"osteoporosis",85,{"name":107,"count":108,"share":47},"diabetes mellitus type 1 (T1D)",70,{"name":110,"count":108,"share":47},"diabetic ketoacidosis (DKA)",{"name":112,"count":46,"share":47},"hypercalcemia",{"name":114,"count":50,"share":47},"Cushing's syndrome",[116,119,122,126,129,132,135,138,140,143],{"name":117,"count":118,"share":96},"Pfizer",163,{"name":120,"count":121,"share":96},"Merck",151,{"name":123,"count":124,"share":125},"Eli Lilly",140,9,{"name":127,"count":128,"share":36},"Novartis",96,{"name":130,"count":131,"share":36},"AbbVie",90,{"name":133,"count":134,"share":47},"Amgen",66,{"name":136,"count":137,"share":47},"Novo Nordisk",59,{"name":139,"count":50,"share":47},"Bristol Myers Squibb",{"name":141,"count":142,"share":19},"Ferring Pharmaceuticals",53,{"name":144,"count":145,"share":57},"Genentech",34,[147,156,164,174,182,191,201,210],{"title":148,"drug":149,"company":151,"phase":152,"disease":153,"finding":154,"url":155},"Characterization of Proptosis Response in the THRIVE Phase 3 Trial of Veligrotug for Active Thyroid Eye Disease (TED)",{"name":150,"slug":150},"veligrotug","Viridian Therapeutics","Phase 3","Graves Orbitopathy (GO)","Proptosis reduction of ≥3 mm occurred in 55% vs 3% and reduction of ≥4 mm occurred in 23% vs 0% of veligrotug vs placebo patients.","https:\u002F\u002Fendo2026.eventscribe.net\u002FfsPopup.asp?Mode=presInfo&PresentationID=1830717",{"title":157,"drug":158,"company":160,"phase":152,"disease":161,"finding":162,"url":163},"Palopegteriparatide Enhances Work Functioning and Productivity in Employed Adults with Chronic Hypoparathyroidism: 156-Week Results from the Pathway Trial",{"name":159,"slug":159},"palopegteriparatide","Ascendis Pharma","hypoparathyroidism","At-work productivity loss improved by 65% for participants in the palopegteriparatide treatment group during the DBP (lowering from 7.7% to 2.7%) and remained low (2.23%) through Week 156.","https:\u002F\u002Fendo2026.eventscribe.net\u002FfsPopup.asp?Mode=presInfo&PresentationID=1846093",{"title":165,"drug":166,"company":170,"phase":152,"disease":171,"finding":172,"url":173},"Long-Term Safety and Efficacy of CAM2029 in Patients with Acromegaly: Results from the ACROINNOVA 2 Open-Label Extension",{"name":167,"slug":168,"named_as":169},"octreotide hydrochloride","octreotide-hydrochloride","CAM2029","Camurus","acromegaly","CAM2029-related adverse events (AEs) were reported by 17 (39.5%) patients; the most frequent were injection site AEs (12 [27.9%]).","https:\u002F\u002Fendo2026.eventscribe.net\u002FfsPopup.asp?Mode=presInfo&PresentationID=1843424",{"title":175,"drug":176,"company":178,"phase":179,"disease":161,"finding":180,"url":181},"Efficacy and Safety of Once-Weekly Canvuparatide in Patients with Hypoparathyroidism: Results from Avail, a Phase 2 Randomized Clinical Trial",{"name":177,"slug":177},"canvuparatide","MBX Biosciences","Phase 2","The most common AEs (canvuparatide vs PBO) were headache (20.8% vs 6.3%), hypercalcemia (18.8% vs 6.3%), arthralgia (14.6% vs 0%), and nausea (12.5% vs 6.3%).","https:\u002F\u002Fendo2026.eventscribe.net\u002FfsPopup.asp?Mode=presInfo&PresentationID=1830416",{"title":183,"drug":184,"company":187,"phase":179,"disease":188,"finding":189,"url":190},"The Liver X Receptor Inverse Agonist TLC-2716 Reduces Triglycerides, Remnant Cholesterol, and Liver Fat in Patients with Severe Hypertriglyceridemia and Metabolic Dysfunction-Associated Steatotic Liver Disease",{"name":185,"slug":186},"TLC-2716","tlc-2716","OrsoBio","hypertriglyceridemia","In the primary analysis, mean (95% CI) placebo-adjusted TG reductions from BL to W4 were 48% (2.7% to 92.9%; p=0.038) with 6 mg and 28% (-15.4% to 72.4%; p=0.193) with 12 mg.","https:\u002F\u002Fendo2026.eventscribe.net\u002FfsPopup.asp?Mode=presInfo&PresentationID=1830589",{"title":192,"drug":193,"company":197,"phase":179,"disease":198,"finding":199,"url":200},"Weight Reduction After 1 Year of Oral Bivamelagon in Acquired Hypothalamic Obesity",{"name":194,"slug":195,"named_as":196},"LB54640","lb54640","bivamelagon","Rhythm Pharmaceuticals","hypothalamic obesity (HO)","Common adverse events (AEs; ≥25%) during 38 weeks of OLE bivamelagon, across all participants, were vomiting (53.8%), nausea (46.2%), and diarrhea (34.6%); of participants with those AEs, >80% were Grade 1 AEs.","https:\u002F\u002Fendo2026.eventscribe.net\u002FfsPopup.asp?Mode=presInfo&PresentationID=1844170",{"title":202,"drug":203,"company":206,"phase":207,"disease":153,"finding":208,"url":209},"Subcutaneous MHB018A, a N Ovel Anti- IGF-1R VHH Antibody, for Thyroid Eye Disease (TED): Results from a Phase 1\u002F2 Study in Patients with Active and Chronic TED",{"name":204,"slug":205},"MHB018A","mhb018a",null,"Phase 1\u002F2","In patients with cTED, treatment with MHB018A resulted in a proptosis response rate of 76% at week 24, with a mean change from baseline of -2.65 mm.","https:\u002F\u002Fendo2026.eventscribe.net\u002FfsPopup.asp?Mode=presInfo&PresentationID=1830710",{"title":211,"drug":212,"company":206,"phase":215,"disease":216,"finding":217,"url":218},"BMN 333 Achieves High Sustained Released Vosoritide Exposure with Favorable Safety: Phase 1 Results That Support Phase 2\u002F3 Trials in Achondroplasia",{"name":213,"slug":214},"BMN 333","bmn-333","Phase 1","achondroplasia (ACH)","Incidence of adverse events (AEs) was similar for BMN 333 (35.7%) and placebo (33.3%); most were mild (grade 1; 9\u002F42 [21.4%] and 2\u002F18 [11.1%], respectively) or moderate (grade 2; 5\u002F42 [11.9%] and 3\u002F18 [16.7%], respectively).","https:\u002F\u002Fendo2026.eventscribe.net\u002FfsPopup.asp?Mode=presInfo&PresentationID=1846286",{"summary":220,"bullets":222},[221],"Small molecules were the most frequent modality (67% of drug-linked abstracts). GR was the most frequent target (8%). Type 2 diabetes mellitus (T2DM) was the most frequent disease (13%).",[223,224,225,226,227],"Pfizer had the largest company share (10% of drug-linked abstracts).","GLP-1 receptor drugs accounted for 8% of drug-linked abstracts.","Peptides were the next most frequent modality (18%).","Obesity was the next most frequent disease (11%).","Merck had the next largest company share (10%).",[],[230],{"name":231,"count":28,"share":25,"previous_count":206,"previous_share":206,"direction":206},"GLP-1 receptor drugs",1793970603075]